CoChat
Sign Up
Cited by 48Monoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer ResearchCancer Immunotherapy and Biomarkers

Clinical Trials of Bispecific Antibody MDX-210 in Women with Advanced Breast or Ovarian Cancer that Overexpresses HER-2/neu

VALONE, FRANK H., KAUFMAN, PETER A., GUYRE, PAUL M., LEWIS, LIONEL D., MEMOLI, VINCENT, ERNSTOFF, MARC S., WELLS, WENDY, BARTH, RICHARD +12 more·1995·Journal of Hematotherapy
DOI 10.1089/scd.1.1995.4.471
Open this paper in CoChat — free account

Abstract

MDX-210 is a bispecific antibody (BsAb) that recognizes Fc gamma R1 on monocytes and macrophages and the cell surface product of the HER-2/neu oncogene, which is overexpressed on some breast and ovarian cancers. Clinical trials have demonstrated that treatment with MDX-210 is well tolerated and that MDX-210 is both immunologically and clinically active. Optimization of the dose and schedule of MDX-210 and development of combination treatments with cytokines that modulate immune effector cells will greatly enhance the efficacy of this novel BsAb construct for treatment of tumours that overexpress HER-2/neu. We envision that MDX-210 will be effective for treating patients with tumors that overexpress HER-2/neu, especially in the minimal disease setting.

Integrity signals

Registry

Crossref · 10.1089/scd.1.1995.4.471

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Preclinical data for MDX-210 indicated that measurable tumor-cell lysis required high bispecific antibody concentrations (0.1-1 mg.mL-1) and effector-to-target cell ratios of at least 40:1, even when human neutrophils prestimulated with IFNγ and G-CSF were used.

    “These results might be explained by preclinical data for MDX-210 indicating that measurable tumor-cell lysis required high bsAb concentrations (0.1-1 mg.mL -1 ) and effector-to-target cell ratios of at least 40:1, even when human neutrophils that had been prestimulated with IFNγ and G-CSF were used. 13”

    From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [13]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
VALONE, F. H., KAUFMAN, P. A., GUYRE, P. M., LEWIS, L. D., MEMOLI, V., ERNSTOFF, M. S., WELLS, W., BARTH, R., DEO, Y., FISHER, J., PHIPPS, K., GRAZIANO, R., MEYER, L., MROZEK-ORLOWSKI, M., WARDWELL, K., GUYRE, V., MORLEY, T. L., ARVIZU, C., WALLACE, P., & FANGER, M. W.
Affiliations
Dartmouth Cancer Center (US)
ORCID
Venue
Journal of Hematotherapy
Publisher
SAGE Publications
Published
1995-10
Volume
4
Issue
5
Pages
471-475
ISSN
1061-6128 (ISSN-L)
DOI
10.1089/scd.1.1995.4.471
OpenAlex
W2084682642
Cited by
48
References
6
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2021: 1 · 2020: 1 · 2018: 3 · 2017: 1 · 2012: 2
FWCI
4.24
Type
journal article
Language
en
Open access
closed
Licence
www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
Locations
  • Journal of Hematotherapy (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (CA23108-15, P30CA023108)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
bispecific antibodies, HER-2/neu overexpression, breast cancer, ovarian cancer, monocytes/macrophages, cytokine combination therapy, dose optimization, minimal residual disease, treatment toxicity
MeSH terms
Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Antibodies, Neoplasm, Antibody Specificity, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Combined Modality Therapy, Drug Administration Schedule, Female, Humans, Hypotension, Immunization, Passive, Neoplasm Proteins, Ovarian Neoplasms, Receptors, Fc, Cohort Studies, Cytokines, Receptors, IgG, Antibodies, Bispecific, Erb-b2 Receptor Tyrosine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review